结合拉文杜斯C和5-arylidenethiazolin-4-one基的药对抗多目标抗癌混合体
Shimaa A Othman1, Ola F Abou-Ghadir1, Varsha Menon2
1Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Assiut University, Assiut 71526, Egypt.
Bioorganic chemistry
|October 18, 2024
概括
来自拉文杜斯C的新型抗癌化合物显示出显著的抗增殖活性. 化合物14b是一种强大的EGFR抑制剂,通过诱导亡和细胞循环停止有效地向癌细胞.
科学领域:
- 药用化学 医学化学
- 药理学 药理学是指药理学的学科.
- 在瘤学瘤学.
背景情况:
- 拉文杜斯C是一种天然产品衍生的抗癌化合物.
- 对拉文杜斯C的修改旨在增强其抗增殖性质.
研究的目的:
- 为了合成和评估新的拉文杜斯C衍生物的抗癌活性.
- 为了确定对抗扩散效应负责的关键结构特征.
主要方法:
- 碳酸基的化和化,并引入5-arylidenethiazolin-4-one部分.
- 对9个癌细胞系和1个正常细胞系进行抗增殖试验.
- 细胞周期分析,诱导亡的研究,EGFR抑制测定,计算对接,以及在中的药理动力学研究.
主要成果:
- 5-arylidenethiazolin-4-one部分对抗癌活性有显著的贡献.
- 甲基是比胺基更有效的;N-乙烯胺是胺基中最有效的.
- 化合物14b对癌细胞表现出高强度 (IC50 1.4-2.5 μM),对正常细胞的毒性最小 (IC50 > 50 μM),诱导了细胞亡,细胞周期停止,并显示出与erlotinib可比的EGFR抑制活性.
结论:
- 化合物14b是一种强效的抗癌药物,具有良好的安全性.
- 14b通过EGFR抑制和诱导亡,表现出多目标潜力.
- 14b可以作为一种有前途的化合物,用于开发新的抗癌疗法.
关键词:
5 - - 氨基酸酸.这是一种抗癌药物.抗扩散药物 抗扩散药物细胞灭亡 (apoptosis) 是一种死亡的过程.脱化 脱化 脱化欧洲农业基金会 (EGFR) 是一个.洗衣机的灰尘在其中.提亚佐林-4-一个.更多相关视频
07:40A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
Published on: May 27, 2021
4.1K
07:20Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents
Published on: May 28, 2014
13.9K
相关概念视频
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Combined Effects of Drugs: Synergism
3.7K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
3.7K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Targets for Drug Action: Overview
6.1K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.1K
